The retinal biologics market size has grown rapidly in recent years. It will grow from $25.17 billion in 2024 to $28.42 billion in 2025 at a compound annual growth rate (CAGR) of 12.9%. The growth in the historic period can be attributed to increased incidence of retinal disorders, aging population, rising awareness and early diagnosis, evolving healthcare infrastructure, and increasing healthcare expenditure.
The retinal biologics market size is expected to see rapid growth in the next few years. It will grow to $44.51 billion in 2029 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to expanding therapeutic applications, personalized medicine, emerging market growth, a strong pipeline of biologics, collaborations and partnerships, government initiatives and support. Major trends in the forecast period include non-invasive delivery methods, real-world evidence utilization, expanded indications, regulatory pathway streamlining, and patient-centric outcomes.
The rising incidence of diabetic eye disease is anticipated to drive the growth of the retinal biologics market in the coming years. Diabetic eye disease is a complication arising from diabetes that can lead to vision loss and blindness among individuals with the condition. Retinal biologics offer the potential for more targeted and effective treatment options, enabling earlier intervention and better outcomes in preventing vision loss related to diabetic eye disease. For example, in December 2023, data from the Australian Bureau of Statistics, a government agency in Australia, indicated that in 2022, 5.3% of the Australian population (approximately 1.3 million people) had diabetes, which represents a significant increase from 3.3%. Thus, the growing prevalence of diabetic eye disease is fueling the expansion of the retinal biologics market.
The growing demand for personalized medicine is anticipated to fuel the expansion of the retinal biologics market. Personalized medicine, tailored to an individual's unique genetic makeup, offers more effective and precise healthcare interventions. In the realm of retinal biologics, personalized medicine strategies are employed to customize treatment approaches based on individual genetic and molecular profiles, optimizing efficacy while minimizing adverse effects. Data from the Personalized Medicine Coalition in January 2023 revealed that out of the 37 new molecular entities (NMEs) approved by the Food and Drug Administration's Center for Drug Evaluation and Research (CDER) in 2022, approximately 34% (12 NMEs) are classified as personalized medicines by the Personalized Medicine Coalition.
A prominent trend gaining traction in the retinal biologics market is product innovation. Leading companies in this market are actively engaged in the development of innovative products to enhance their market position and gain a competitive edge. Notably, F. Hoffmann-La Roche Ltd., a Switzerland-based healthcare company, announced in May 2023 that the U.S. Food and Drug Administration had accepted the company's supplemental biologics license application (sBLA) for Vabysmo (faricimab), designed for the treatment of macular edema following retinal vein occlusion (RVO). Vabysmo is a bispecific antibody that has demonstrated early and persistent visual improvement, achieving the primary endpoint of non-inferiority to aflibercept. This product marks a significant advancement as the first bispecific antibody approved for the eye to treat 'wet' age-related macular degeneration and diabetic macular edema.
Strategic partnerships are a prominent approach adopted by major companies in the retinal biologics market to fortify their market presence and offer innovative solutions. Biogen Inc., a U.S.-based biotechnology company, entered into a strategic partnership with Samsung Bioepis Co., Ltd., a South Korean biotechnology company, in June 2022. This collaboration led to the launch of BYOOVIZ, a biosimilar for retinal vascular disorders. BYOOVIZ holds potential for substantial cost savings within the U.S. healthcare system while expanding access for patients with retinal disorders.
In January 2023, Coherus BioSciences Inc., a U.S.-based biosimilar therapeutics company, secured exclusive commercialization rights to FYB203, a biosimilar candidate of Eylea (aflibercept), from Klinge Biopharma GmbH in the United States. This strategic acquisition expands Coherus' market opportunity in the anti-VEGF medications segment, supporting mid-to-long-term growth and revenue potential. Klinge Biopharma GmbH is a Germany-based firm specializing in anti-VEGF medications.
Major companies operating in the retinal biologics market include Regeneron Pharmaceuticals Inc., AbbVie Inc., MeiraGTx Limited, Oxurion NV, Novartis AG, Amgen Inc., Spark Therapeutics Inc., Bayer AG, Bausch Health Companies Inc., Merck & Co. Inc., Santen Pharmaceutical Co. Ltd., Pfizer Inc., Boehringer Ingelheim, Eyenovia Inc., EyePoint Pharmaceuticals Inc., Iveric Bio Inc., Kodiak Sciences Inc., Aerie Pharmaceuticals Inc., Alimera Sciences Inc., Ocular Therapeutix Inc., Acucela Inc., Clearside Biomedical Inc., Ophthotech Corporation, Xcovery Holdings, Athenex Inc., Fidia Farmaceutici S.p.A, Eton Pharmaceuticals Inc.
North America was the largest region in the retinal biologics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the retinal biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the retinal biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Retinal biologics refer to bioengineered macromolecules that are implanted inside the eyes to treat chronic retinal diseases. These highly precise compounds target inflammatory mediators and are used in the treatment of various inflammatory, corneal, and retinal medical conditions.
The main types of retinal biologics include vascular endothelial growth factor (VEGF)-A antagonists and tumor necrosis factor (TNF)-A inhibitors. A VEGF-A antagonist is a substance that inhibits the activity of vascular endothelial growth factor, a potent angiogenic factor and an essential growth factor for vascular endothelial cells. These biologics are administered for various indications, including macular degeneration, diabetic retinopathy, uveitis, diabetic macular edema, and others. They are typically available in hospitals, pharmacies, specialty clinics, online pharmacies, and other healthcare facilities.
The retinal biologics market research report is one of a series of new reports that provides retinal biologics market statistics, including retinal biologics industry global market size, regional shares, competitors with a retinal biologics market share, detailed retinal biologics market segments, market trends, and opportunities, and any further data you may need to thrive in the retinal biologics industry. This retinal biologics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The retinal biologics market consists of sales of ranibizumab, aflibercept, and brolucizumab. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The retinal biologics market size is expected to see rapid growth in the next few years. It will grow to $44.51 billion in 2029 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to expanding therapeutic applications, personalized medicine, emerging market growth, a strong pipeline of biologics, collaborations and partnerships, government initiatives and support. Major trends in the forecast period include non-invasive delivery methods, real-world evidence utilization, expanded indications, regulatory pathway streamlining, and patient-centric outcomes.
The rising incidence of diabetic eye disease is anticipated to drive the growth of the retinal biologics market in the coming years. Diabetic eye disease is a complication arising from diabetes that can lead to vision loss and blindness among individuals with the condition. Retinal biologics offer the potential for more targeted and effective treatment options, enabling earlier intervention and better outcomes in preventing vision loss related to diabetic eye disease. For example, in December 2023, data from the Australian Bureau of Statistics, a government agency in Australia, indicated that in 2022, 5.3% of the Australian population (approximately 1.3 million people) had diabetes, which represents a significant increase from 3.3%. Thus, the growing prevalence of diabetic eye disease is fueling the expansion of the retinal biologics market.
The growing demand for personalized medicine is anticipated to fuel the expansion of the retinal biologics market. Personalized medicine, tailored to an individual's unique genetic makeup, offers more effective and precise healthcare interventions. In the realm of retinal biologics, personalized medicine strategies are employed to customize treatment approaches based on individual genetic and molecular profiles, optimizing efficacy while minimizing adverse effects. Data from the Personalized Medicine Coalition in January 2023 revealed that out of the 37 new molecular entities (NMEs) approved by the Food and Drug Administration's Center for Drug Evaluation and Research (CDER) in 2022, approximately 34% (12 NMEs) are classified as personalized medicines by the Personalized Medicine Coalition.
A prominent trend gaining traction in the retinal biologics market is product innovation. Leading companies in this market are actively engaged in the development of innovative products to enhance their market position and gain a competitive edge. Notably, F. Hoffmann-La Roche Ltd., a Switzerland-based healthcare company, announced in May 2023 that the U.S. Food and Drug Administration had accepted the company's supplemental biologics license application (sBLA) for Vabysmo (faricimab), designed for the treatment of macular edema following retinal vein occlusion (RVO). Vabysmo is a bispecific antibody that has demonstrated early and persistent visual improvement, achieving the primary endpoint of non-inferiority to aflibercept. This product marks a significant advancement as the first bispecific antibody approved for the eye to treat 'wet' age-related macular degeneration and diabetic macular edema.
Strategic partnerships are a prominent approach adopted by major companies in the retinal biologics market to fortify their market presence and offer innovative solutions. Biogen Inc., a U.S.-based biotechnology company, entered into a strategic partnership with Samsung Bioepis Co., Ltd., a South Korean biotechnology company, in June 2022. This collaboration led to the launch of BYOOVIZ, a biosimilar for retinal vascular disorders. BYOOVIZ holds potential for substantial cost savings within the U.S. healthcare system while expanding access for patients with retinal disorders.
In January 2023, Coherus BioSciences Inc., a U.S.-based biosimilar therapeutics company, secured exclusive commercialization rights to FYB203, a biosimilar candidate of Eylea (aflibercept), from Klinge Biopharma GmbH in the United States. This strategic acquisition expands Coherus' market opportunity in the anti-VEGF medications segment, supporting mid-to-long-term growth and revenue potential. Klinge Biopharma GmbH is a Germany-based firm specializing in anti-VEGF medications.
Major companies operating in the retinal biologics market include Regeneron Pharmaceuticals Inc., AbbVie Inc., MeiraGTx Limited, Oxurion NV, Novartis AG, Amgen Inc., Spark Therapeutics Inc., Bayer AG, Bausch Health Companies Inc., Merck & Co. Inc., Santen Pharmaceutical Co. Ltd., Pfizer Inc., Boehringer Ingelheim, Eyenovia Inc., EyePoint Pharmaceuticals Inc., Iveric Bio Inc., Kodiak Sciences Inc., Aerie Pharmaceuticals Inc., Alimera Sciences Inc., Ocular Therapeutix Inc., Acucela Inc., Clearside Biomedical Inc., Ophthotech Corporation, Xcovery Holdings, Athenex Inc., Fidia Farmaceutici S.p.A, Eton Pharmaceuticals Inc.
North America was the largest region in the retinal biologics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the retinal biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the retinal biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Retinal biologics refer to bioengineered macromolecules that are implanted inside the eyes to treat chronic retinal diseases. These highly precise compounds target inflammatory mediators and are used in the treatment of various inflammatory, corneal, and retinal medical conditions.
The main types of retinal biologics include vascular endothelial growth factor (VEGF)-A antagonists and tumor necrosis factor (TNF)-A inhibitors. A VEGF-A antagonist is a substance that inhibits the activity of vascular endothelial growth factor, a potent angiogenic factor and an essential growth factor for vascular endothelial cells. These biologics are administered for various indications, including macular degeneration, diabetic retinopathy, uveitis, diabetic macular edema, and others. They are typically available in hospitals, pharmacies, specialty clinics, online pharmacies, and other healthcare facilities.
The retinal biologics market research report is one of a series of new reports that provides retinal biologics market statistics, including retinal biologics industry global market size, regional shares, competitors with a retinal biologics market share, detailed retinal biologics market segments, market trends, and opportunities, and any further data you may need to thrive in the retinal biologics industry. This retinal biologics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The retinal biologics market consists of sales of ranibizumab, aflibercept, and brolucizumab. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Retinal Biologics Market Characteristics3. Retinal Biologics Market Trends and Strategies4. Retinal Biologics Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid and Recovery on the Market32. Global Retinal Biologics Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Retinal Biologics Market34. Recent Developments in the Retinal Biologics Market
5. Global Retinal Biologics Growth Analysis and Strategic Analysis Framework
6. Retinal Biologics Market Segmentation
7. Retinal Biologics Market Regional and Country Analysis
8. Asia-Pacific Retinal Biologics Market
9. China Retinal Biologics Market
10. India Retinal Biologics Market
11. Japan Retinal Biologics Market
12. Australia Retinal Biologics Market
13. Indonesia Retinal Biologics Market
14. South Korea Retinal Biologics Market
15. Western Europe Retinal Biologics Market
16. UK Retinal Biologics Market
17. Germany Retinal Biologics Market
18. France Retinal Biologics Market
19. Italy Retinal Biologics Market
20. Spain Retinal Biologics Market
21. Eastern Europe Retinal Biologics Market
22. Russia Retinal Biologics Market
23. North America Retinal Biologics Market
24. USA Retinal Biologics Market
25. Canada Retinal Biologics Market
26. South America Retinal Biologics Market
27. Brazil Retinal Biologics Market
28. Middle East Retinal Biologics Market
29. Africa Retinal Biologics Market
30. Retinal Biologics Market Competitive Landscape and Company Profiles
31. Retinal Biologics Market Other Major and Innovative Companies
35. Retinal Biologics Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Retinal Biologics Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on retinal biologics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for retinal biologics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The retinal biologics market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Drug Class: Vascular Endothelial Growth Factor (VEGF)-a Antagonist; Tumor Necrosis Factor (TNF)-a Inhibitor2) By Indication: Macular Degeneration; Diabetic Retinopathy; Uveitis; Diabetic Macular Edema; Other Indications
3) By Distribution Channel: Hospitals; Pharmacies; Specialty Clinics; Online Pharmacies; Other Distribution Channels
Subsegments:
1) By Vascular Endothelial Growth Factor (VEGF)-a Antagonist: Monoclonal Antibodies; Small Molecule Inhibitors2) By Tumor Necrosis Factor (TNF)-a Inhibitor: Monoclonal Antibodies; Fusion Proteins
Key Companies Mentioned: Regeneron Pharmaceuticals Inc.; AbbVie Inc.; MeiraGTx Limited; Oxurion NV; Novartis AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Regeneron Pharmaceuticals Inc.
- AbbVie Inc.
- MeiraGTx Limited
- Oxurion NV
- Novartis AG
- Amgen Inc.
- Spark Therapeutics Inc.
- Bayer AG
- Bausch Health Companies Inc.
- Merck & Co. Inc.
- Santen Pharmaceutical Co. Ltd.
- Pfizer Inc.
- Boehringer Ingelheim
- Eyenovia Inc.
- EyePoint Pharmaceuticals Inc.
- Iveric Bio Inc.
- Kodiak Sciences Inc.
- Aerie Pharmaceuticals Inc.
- Alimera Sciences Inc.
- Ocular Therapeutix Inc.
- Acucela Inc.
- Clearside Biomedical Inc.
- Ophthotech Corporation
- Xcovery Holdings
- Athenex Inc.
- Fidia Farmaceutici S.p.A
- Eton Pharmaceuticals Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | February 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 28.42 Billion |
| Forecasted Market Value ( USD | $ 44.51 Billion |
| Compound Annual Growth Rate | 11.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 27 |
